Sarachana Tewarit, Dahiya Neetu, Simhadri Vijaya L, Pandey Gouri Shankar, Saini Surbhi, Guelcher Christine, Guerrera Michael F, Kimchi-Sarfaty Chava, Sauna Zuben E, Atreya Chintamani D
Laboratory of Cellular Hematology, Division of Hematology Research and Review, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland 20993, United States of America; Department of Clinical Chemistry, Faculty of Allied Health Sciences, Chulalongkorn University, Bangkok, 10330, Thailand.
Laboratory of Cellular Hematology, Division of Hematology Research and Review, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland 20993, United States of America.
PLoS One. 2015 Jul 15;10(7):e0132433. doi: 10.1371/journal.pone.0132433. eCollection 2015.
Hemophilia A (HA) is a bleeding disorder caused by deficiency of functional plasma clotting factor VIII (FVIII). Genetic mutations in the gene encoding FVIII (F8) have been extensively studied. Over a thousand different mutations have been reported in the F8 gene. These span a diverse range of mutation types, namely, missense, splice-site, deletions of single and multiple exons, inversions, etc. There is nonetheless evidence that other molecular mechanisms, in addition to mutations in the gene encoding the FVIII protein, may be involved in the pathobiology of HA. In this study, global small ncRNA expression profiling analysis of whole blood from HA patients, and controls, was performed using high-throughput ncRNA microarrays. Patients were further sub-divided into those that developed neutralizing-anti-FVIII antibodies (inhibitors) and those that did not. Selected differentially expressed ncRNAs were validated by quantitative reverse transcription-polymerase chain reaction (qRT-PCR) analysis. We identified several ncRNAs, and among them hsa-miR-1246 was significantly up-regulated in HA patients. In addition, miR-1246 showed a six-fold higher expression in HA patients without inhibitors. We have identified an miR-1246 target site in the noncoding region of F8 mRNA and were able to confirm the suppressory role of hsa-miR-1246 on F8 expression in a stable lymphoblastoid cell line expressing FVIII. These findings suggest several testable hypotheses vis-à-vis the role of nc-RNAs in the regulation of F8 expression. These hypotheses have not been exhaustively tested in this study as they require carefully curated clinical samples.
甲型血友病(HA)是一种由于功能性血浆凝血因子VIII(FVIII)缺乏而导致的出血性疾病。编码FVIII(F8)的基因中的基因突变已得到广泛研究。F8基因中已报道了一千多种不同的突变。这些突变涵盖了多种类型,即错义突变、剪接位点突变、单个和多个外显子的缺失、倒位等。然而,有证据表明,除了编码FVIII蛋白的基因中的突变外,其他分子机制可能也参与了HA的病理生物学过程。在本研究中,使用高通量非编码RNA微阵列对HA患者和对照的全血进行了全局小非编码RNA表达谱分析。患者进一步分为产生中和性抗FVIII抗体(抑制剂)的患者和未产生的患者。通过定量逆转录-聚合酶链反应(qRT-PCR)分析对选定的差异表达非编码RNA进行了验证。我们鉴定出了几种非编码RNA,其中hsa-miR-1246在HA患者中显著上调。此外,miR-1246在没有抑制剂的HA患者中的表达高六倍。我们在F8 mRNA的非编码区域鉴定出一个miR-1246靶位点,并能够在表达FVIII的稳定淋巴母细胞系中证实hsa-miR-1246对F8表达的抑制作用。这些发现提出了几个关于非编码RNA在F8表达调控中作用的可检验假设。由于这些假设需要精心挑选的临床样本,因此在本研究中尚未进行详尽的检验。